Drug intelligence / Profile preview

tinidazole + fluconazole + metronidazole + clotrimazole

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Topical, Intravaginal
01

Overview

This is a combination drug containing four active pharmaceutical ingredients: tinidazole, fluconazole, metronidazole, and clotrimazole. All are anti-infective agents but with different mechanisms of action and antimicrobial spectra. Tinidazole and metronidazole are nitroimidazoles effective against anaerobic bacteria and protozoa by damaging microbial DNA. Fluconazole is a triazole antifungal that inhibits fungal ergosterol synthesis, disrupting cell membrane formation. Clotrimazole is an imidazole antifungal that also inhibits ergosterol synthesis in fungi but is typically used topically or intravaginally. This combination would theoretically provide broad-spectrum coverage for mixed vaginal infections (bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis), targeting both bacterial and fungal pathogens simultaneously. While combinations of two or three of these agents (e.g., tinidazole + fluconazole; metronidazole + clotrimazole) are documented in clinical use for syndromic management of vaginal discharge[1][3][6], there is no evidence from the provided sources or standard references for a marketed product containing all four together as a single formulation.

02

Targets

NeuraminidaseCYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on tinidazole + fluconazole + metronidazole + clotrimazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tinidazole + fluconazole + metronidazole + clotrimazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call